Bachem is excited to report excellent results for 2021. The CEC is looking back on 2021 successes and is excited for what is planned for 2022.
A huge thank you to the entire Team Bachem for this amazing group effort.
• Group sales increase to CHF 503.2 million, up 25.2% year-on-year.
• EBITDA increases from CHF 122.6 million to CHF 157.4 million with a margin of 31.3%.
• Operating income EBIT increases from CHF 96.7 million to CHF 128.9 million with a margin of 25.6%.
• Net income increases from CHF 78.1 million to CHF 114.7 million with a margin of 22.8%.
• Total investments of CHF 130.7 million and creation of 166 new jobs, 149 of them in Switzerland.
• Board of Directors proposes to increase the dividend by CHF 0.25 to CHF 3.50 per share.
• Capital increase of CHF 571.6 million net strengthens equity base and secures capacity expansion plans and financial independence.
Outlook:
• Bachem expects sales to increase by an average of 15% per year over the five-year period 2022-2026.
• Operating income (EBIT) is expected to increase at a higher percentage rate than sales growth within this period.
• The target of CHF 100 million in sales from the oligonucleotides business is expected to be reached in 2023.
• Bachem is pursuing an investment program across all sites to expand capacity. The launch of operations for the world's most modern and largest building for peptide and oligonucleotide production in Bubendorf is planned for 2024. A third site in Switzerland is to strengthen the production network by the end of the decade.
Featuring
Thomas Meier, Chief Executive Officer (CEO)
Alain Schaffter, Chief Financial Officer (CFO)
Günther Loidl, Chief Technology Officer (CTO)
Torsten Wöhr, Chief Marketing Officer (CMO)
Anne-Kathrin Stoller, Chief Marketing Officer (CMO) 2021
Roland Schürmann, Chief Operations Officer (COO)
The full annual report can be found here: www.bachem.com...
--------------------------------------------------------------------------------------------------------------------
About Bachem:
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Learn more about our products and services at www.bachem.com/
28 авг 2024